Hipolin Limited has submitted its quarterly compliance certificate under SEBI regulations to the Bombay Stock Exchange, fulfilling mandatory regulatory requirements for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The company filed its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 on April 10, 2026. Company Secretary and Compliance Officer Anjali Maheshwari signed the submission, which was addressed to the Listing Department of Bombay Stock Exchange Limited.

Registrar Confirmation

MUFG Intime India Private Limited, serving as Hipolin's Registrar and Transfer Agent, issued a confirmation certificate dated April 1, 2026. The certificate was signed by Ashok Shetty, Sr. Vice President-Corporate Registry, confirming the company's compliance with dematerialisation requirements.

The registrar confirmed that securities received from depository participants for dematerialisation during the quarter were properly processed and that all security certificates were mutilated and cancelled after due verification. The confirmation also verified that depositories' names were substituted in the register of members as registered owners within prescribed timelines.

Company Information

Hipolin Limited operates from its registered office located at Survey No. 2/2, Behind Safeexpress Logistic, Changodar, Dist. Ahmedabad 382213. The company holds CIN L24240GJ1994PLCO21719 and maintains its listing on the Bombay Stock Exchange under scrip code 530853.

MUFG Intime India Details

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, serves as the registrar and transfer agent. The company operates from its registered address at C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai - 400083, with CIN U67190MH1999PTC118368.

Hipolin Ltd has announced the approval of its quarterly financial results for the third quarter of fiscal year 2026. The company's Board of Directors convened on February 14, 2026, to review and approve key financial documents in accordance with regulatory requirements.

Board Meeting Outcome

The board meeting was held on Saturday, February 14, 2026, where directors considered and approved both standalone and consolidated unaudited financial results for the quarter ended December 31, 2025. The meeting was conducted with specific timing parameters as outlined in the regulatory filing.

Financial Results Approval

The primary agenda item involved the consideration and approval of the company's financial performance for the quarter ended December 31, 2025. The board approved both standalone and consolidated unaudited financial results, ensuring comprehensive coverage of the company's financial position.

The approved financial results include a Limited Review Report provided by the company's Statutory Auditor, adding an additional layer of verification to the financial data. This review report accompanies the unaudited results as part of the standard regulatory compliance process.

Regulatory Compliance and Filing

The announcement was made pursuant to Regulation 30 and Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company filed this information with BSE Limited under scrip code 530853 and scrip ID HIPOLIN, ensuring proper disclosure to market participants and regulatory authorities.

The filing was signed by Anjali Maheshwari, who serves as the Company Secretary and Compliance Officer for Hipolin Ltd. The digital signature was applied on February 14, 2026, at 18:18:57 +05'30', confirming the authenticity and timing of the regulatory submission to BSE Limited at Dalal Street, Fort, Mumbai.